- Home
- PLG vs ADCT Comparison
PLG vs ADCT Comparison
Compare PLG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLG
- ADCT
- Stock Information
- Founded
- PLG 2000
- ADCT 2011
- Country
- PLG Canada
- ADCT Switzerland
- Employees
- PLG N/A
- ADCT N/A
- Industry
- PLG
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PLG
- ADCT Health Care
- Exchange
- PLG Nasdaq
- ADCT Nasdaq
- Market Cap
- PLG 122.2M
- ADCT 127.9M
- IPO Year
- PLG N/A
- ADCT 2020
- Fundamental
- Price
- PLG $1.25
- ADCT $1.28
- Analyst Decision
- PLG
- ADCT Strong Buy
- Analyst Count
- PLG 0
- ADCT 5
- Target Price
- PLG N/A
- ADCT $7.75
- AVG Volume (30 Days)
- PLG 583.1K
- ADCT 235.3K
- Earning Date
- PLG 04-11-2025
- ADCT 05-14-2025
- Dividend Yield
- PLG N/A
- ADCT N/A
- EPS Growth
- PLG N/A
- ADCT N/A
- EPS
- PLG N/A
- ADCT N/A
- Revenue
- PLG N/A
- ADCT $70,837,000.00
- Revenue This Year
- PLG N/A
- ADCT $6.82
- Revenue Next Year
- PLG N/A
- ADCT $18.56
- P/E Ratio
- PLG N/A
- ADCT N/A
- Revenue Growth
- PLG N/A
- ADCT 1.84
- 52 Week Low
- PLG $0.99
- ADCT $1.05
- 52 Week High
- PLG $2.27
- ADCT $4.83
- Technical
- Relative Strength Index (RSI)
- PLG 53.90
- ADCT 43.00
- Support Level
- PLG $1.15
- ADCT $1.23
- Resistance Level
- PLG $1.38
- ADCT $1.49
- Average True Range (ATR)
- PLG 0.05
- ADCT 0.08
- MACD
- PLG 0.00
- ADCT 0.00
- Stochastic Oscillator
- PLG 90.91
- ADCT 25.00
About PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).